EGFR negative

P=N/A, N=142, Not yet recruiting, Nanjing Drum Tower Hospital; Nanjing Drum Tower Hospital

P=N/A, N=60, Completed, Guiyang Public Health Clinical Center; Guiyang Public Health Clinical Center

P2, N=34, Not yet recruiting, The General Hospital of the Eastern Theater Command of the People's Liberation Army of China; The General Hospital of the Eastern Theater Command of t

P1, N=10, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University

P=N/A, N=150, Recruiting, University of Malaya

P2, N=60, Recruiting, Shanghai Henlius Biotech | Not yet recruiting --> Recruiting

The prognostic nomogram showed promising prediction efficacy and is expected to predict the prognosis of "driver-gene-negative" LUAD. The easy-to-use nomogram and the enriched pathways can help clinical decision-making, guide follow-up planning, and develop new therapeutic targets.

P2, N=41, Recruiting, Tianjin Medical University Cancer Institute and Hospital

EGFR amplification was frequent in OSCC, and CDKN2A deletion was prevalent in OED, supporting their use as molecular markers for differential diagnoses. FISH for EGFR/CDKN2A and HRAS IHC can stratify OSCC by diagnosis and prognosis, enabling practical molecular subclassification, including EGFR-negative cases.

However, there is concern that overall survival might be shortened if CATs develop. Therefore, the possibility of developing CATs in EGFR-positive NSCLC patients must be addressed.

Never and light smokers with stage IV NSCLC displayed distinct features. The high prevalence of actionable EGFR alterations underscores the importance of comprehensive molecular testing. Region-specific data should inform precision oncology strategies and the design of prospective trials targeting non-traditional risk groups.

We estimated that 8602 patients with newly diagnosed esophageal cancers would be eligible for adjuvant nivolumab...Among NSCLC patients who may undergo resection and qualify for adjuvant therapy, 70,602 patients are anticipated to be epidermal growth factor receptor-negative and treated with adjuvant atezolizumab or pembrolizumab...The cost to treat 1 patient with adjuvant osimertinib was $556,000, with an incident cohort cost of $8 billion...Immune and targeted therapy in operable thoracic patients is associated with a significant cost burden. Studies are needed to assess cost-effectiveness to ensure optimal resource allocation and improve patient outcomes.